What's Going With Annovis Bio Shares Tuesday?
What's Going With Annovis Bio Shares Tuesday?
Annovis Bio, Inc (NYSE:ANVS) stock is trending Tuesday. The company eelier announced new data from its Phase III Parkinson's study.
annovis bio股票（紐交所：ANVS）於週二呈現趨勢。該公司較早前宣佈了其第三期帕金森症研究的新數據。
What Happened: The study showed improvements on the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) following treatment with buntanetap.
發生了什麼：這項研究顯示，在接受buntanetap治療後，統一帕金森氏病評分量表（MDS-UPDRS）有所改善。
The findings demonstrated that the placebo group experienced cognitive deterioration throughout the study, whereas the treatment groups experienced no further deterioration.
研究結果表明，安慰劑組在研究期間出現認知惡化，而治療組未出現進一步惡化。
In patients with mild dementia, cognition declined more rapidly in the placebo group than in those treated with 10mg buntanetap. Treatment with 20mg buntanetap led to significant cognitive improvements compared to the placebo group.
在輕度癡呆患者中，與接受10mg buntanetap治療的患者相比，安慰劑組的認知能力下降更快。 與安慰劑組相比，接受20mg buntanetap治療的患者認知能力顯著提高。
Also, motor function improved in Parkinson's patients with a diagnosis of over three years who had experienced measurable deficits. Lastly, Postural Instability and Gait Difficulty patients responded better to the treatment and improved more compared to Parkinson's patients.
此外，在帕金森病患者中，確診超過三年且存在可測量的缺陷的患者的運動功能也有所改善，姿勢不穩和步態困難患者對治療反應更好，改善也更明顯。
ANVS Price Action: Annovis Bio stock is up 8.16% at $5.70, according to Benzinga Pro.
根據Benzinga Pro的數據，Annovis Bio股票價格上漲了8.16％，達到5.70美元。
Image: Unsplash/ Volodymyr Hryshchenko
圖片：Unsplash / Volodymyr Hryshchenko
譯文內容由第三人軟體翻譯。